Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACB Clear all
Withdrawn Phase 4 Interventional

Exparel vs Exparel Plus ACB in TKAs

NCT02365727
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Liposomal bupivacaine, Ropivacaine, Epinephrine, Clonidine, Saline
Drug
Lead sponsor
The Hawkins Foundation
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

NCT04757974
View directory record Official record
Conditions
HIV Infections
Interventions
Fostemsavir 600 mg, Fostemsavir 200 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 23, 2026, 8:26 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

NCT04131556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

NCT06290102
View directory record Official record
Conditions
Asthma
Interventions
TEV-56248, Fp MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Mobile, Alabama • Long Beach, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

NCT05578846
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Treatment A, Treatment B, Treatment C
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

NCT03901313
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A - 400 mg Fasting, Treatment B - 400 mg Fed, Treatment C - 200 mg Fed
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Not applicable Interventional

Adductor Canal Blocks With Bupivacaine and Magnesium After Same-day Discharge Total Knee Arthroplasty Improve Post-operative Pain Relief and Decrease Opioid Consumption: a Prospective Randomized Controlled Trial

NCT05004636
View directory record Official record
Conditions
Post-operative Pain, Acute
Interventions
Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

NCT04969497
View directory record Official record
Conditions
Migraine
Interventions
Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying

NCT00685477
View directory record Official record
Conditions
Healthy
Interventions
Experimental Sequence ABC, Experimental Sequence ACB, Experimental Sequence BAC, Experimental Sequence BCA, Experimental Sequence CAB, Experimental Sequence CBA
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 23, 2026, 8:26 AM EDT
Withdrawn Not applicable Interventional

ACB + IPACK Block With or Without Local Infiltration in RA-TKA

NCT03840122
View directory record Official record
Conditions
Knee Arthropathy
Interventions
ACB + IPACK block with injection of local anesthetic, ACB + IPACK block without injection
Other
Lead sponsor
University of Louisville
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

NCT00979875
View directory record Official record
Conditions
Healthy
Interventions
Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 4 Interventional Results available

iPACK for Post-op Pain Following ACL Reconstruction

NCT05498870
View directory record Official record
Conditions
ACL Injury, Post Operative Pain
Interventions
Adductor Canal Block (ACB) Only, Adductor Canal Block (ACB) + iPACK Block
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 4 Interventional Results available

Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)

NCT03094663
View directory record Official record
Conditions
Knee Arthropathy
Interventions
Bupivacaine with epinephrine, Methylprednisolone, Cefazolin, 8 MHz. Chiba needle, Bupivacaine with Dexamethasone, Bupivacaine 25cc, Bupivacaine 20cc, Dexamethasone
Drug · Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 4 Interventional Results available

Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery

NCT05720949
View directory record Official record
Conditions
ACL, Anterior Cruciate Ligament Injuries
Interventions
Genicular Nerve Block with bupivacaine and preservative free dexamethasone
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

NCT05319899
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 4 Interventional Results available

Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block

NCT03401450
View directory record Official record
Conditions
ACL Surgery
Interventions
ACB within true AC with bupivacaine 0.5% 20cc, ACB proximal to true AC with bupivacaine 0.5% 20cc
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Not applicable Interventional

Analgesic Efficacy of Anterior Femoral, Genicular and Adductor Canal Nerve Block

NCT02548104
View directory record Official record
Conditions
Pain, Postoperative
Interventions
ACB, ACB + iPACK
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

NCT00862849
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Lispro, Regular Human Insulin, rHuPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Not applicable Interventional

Risk of Falling After CFNB Versus ACB

NCT02314832
View directory record Official record
Conditions
Falls, Total Knee Arthroplasty (TKA), Osteoarthritis
Interventions
adductor canal block, femoral nerve block
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants

NCT02230046
View directory record Official record
Conditions
Healthy
Interventions
Abiraterone acetate (Treatment A), Abiraterone acetate (Treatment B)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 4 Interventional Results available

Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty

NCT02777749
View directory record Official record
Conditions
Osteoarthritis
Interventions
Bupivacaine
Drug
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 23, 2026, 8:26 AM EDT
Recruiting Not applicable Interventional

Effectiveness of Exparel Anesthetic Administered by the Surgeon During Knee Surgery

NCT06946368
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Intra-articular Posteromedial Surgeon Administered (IPSA) Block of EXPAREL, Adductor Canal Block (ACB) and Local Local Infiltration Analgesia of EXPAREL, Local Infiltration Analgesia (LIA) of EXPAREL
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 8:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

NCT02345707
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Cabotegravir 30 mg current formulation, Cabotegravir 30 mg micronized new formulation 500 M, Cabotegravir 30 mg unmicronized new formulation 500 U, Cabotegravir 30 mg micronized new formulation 650 M, Cabotegravir 30 mg unmicronized new formulation 650 U
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 23, 2026, 8:26 AM EDT